Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Graystone who wrote (3281)	8/21/1998 2:34:00 PM
From: Graham Marshman	Read Replies (4) \| Respond to of 4028

Boy Graystone, you sure dug that reference up out of the past, July 10. In your post I was referring to, you were mentioning recent FDA talk. This was initiated by Celeryroot on Aug 19: from Celeryroot, Aug 19, to me "While you are answering questions: Who is the Industrial Review Board? Why does CYGS require their acceptance? THX" However, re your questions on my Jul 10 post: Who is going to pay the FDA toll. What toll would that be Graham. * As was clear in the context, that was the cost of approving a vector/antisense package So you are saying Cryogenics will be participating in a $300 Million dollar market in about 18 months, kind of optimistic isn't it. Are you sure that the FDA will approve things that quick. * Yes it was over-optimistic and not well expressed. (Despite rumors to the contrary, I'm not always right) What I was trying to get at was potential CYGS revenues as part of a growing antisense market, without too much consideration of when they could intersect it. You know, that market size thing again. As you see at the bottom of the original post, I did say I was still pondering this. Are the vectors in pre-clinical now? * Answered that to Celery the other day. My opinion, yes. I see you mention animal testing, are you saying that is being done also ? * No, in fact I was saying telomere animal testing was being delayed in favor of the antisense delivery vector work. Another reference to MSFT, are you guys all right over here. * It was, and still is, a clear and useful comparison in product positioning. As the delivery vector, CYGS is similar to the OS of antisense. In summary, I won't always be right, but I will always be honest and I'm always ready to consider alternate views and good input. Graham